Association of early childhood Nevirapine-based ART regimens with poorer neuropsychological outcomes compared to Lopinavir/ritonavir in HIV-positive children

Lee Fairlie1, Miriam Chemoff2, Mark F. Cotton2, Mutswashe Bwakura-Dangarembizi3, Avy Volien4, Itziar Familiar-Lopez5, Linda Barlow-Mosha6, Portia Kamthunzi6, Katie McCarthy7, Patrick Jean-Philippe8, Barbara Laughlin9, Paul E. Palumbo10,11, Michael J. Boivin12,13

BACKGROUND
IMPAACT P1104s compared neuropsychological outcomes over 96 weeks in children living with HIV (CLHHIV) with matched HIV-unexposed (HU) and HIV-exunfected (HEU) children, aged 5 to 11 years at 6 sites in Sub-Saharan Africa. Here, we explore associations with neuropsychological outcomes in the CLHHIV cohort including clinical, immunological and medication-related factors.

METHODS
CLHHIV had participated in IMPAACT P1060, comparing efficacy of nevirapine (NVP) and lopinavir/ritonavir (LPV/r) in young CLHHIV < 3 years, also on lamivudine & zidovudine. P1104s was a follow-on study evaluating neuropsychological performance in CLHHIV from P1060, HU and HEU children. 96% of eligible P1060 participants, enrolled in P1104s. Neuropsychological evaluations (KABC cognitive ability, BRIEF executive function - transformed to lower score being worse, TOVA attention-impulsivity and BOT-2 motor) were at 0, 48 and 96 weeks. In HIV+ children, clinical, antiretroviral and laboratory (immunological and virological) data from P1060 were combined with clinical and neuropsychological and caregiver data from P1104s to explore associations with neuropsychological outcomes. Linear mixed models with restricted maximum likelihood estimation (REML) and robust fixed effect error estimates were used to explore test scores were associated across time with the growth, clinical history, HIV disease severity and treatment markers (screening characteristics) and to estimate these associations. Personal and caregiver characteristics were controlled for. Slope estimates and adjusted means with 95% confidence intervals were presented. Tests of statistical significance were two-sided and 5% error rates were used.

RESULTS
The 246 CLHHIV (45% male, mean age at P1104s entry 7.1 yrs (SD 1.2)) had median ART initiation at 15 months (IQR 8.2, 25.2), nadir CD4 count of 632 cells/mm³ (IQR 427, 874); 233 (95%) had a peak viral load >100,000 copies/ml. 164 (67%), 7 (3%) and 71 (29%) were receiving LPV/r, efavirenz (EFV) - and NVP-based ART respectively at 1104s entry; 61% had ≥ 3 stage WHO clinical stage.

Risk factors for lower neuropsychological scores on all KABC, TOVA and BOT-2 domains included receiving NVP/EFV at P1104s entry rather than LPV/r.

Other risk factors included low birth weight, WHO stage 4 disease and serious illness, but these were not consistent across all domains

Elevated VL was not a risk factor.

Table 1. Risk factors for lower neuropsychological performance across cognitive domains

<table>
<thead>
<tr>
<th>Domain</th>
<th>Estimate (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>KABC VI</td>
<td>-0.01 (0.02, 0.00)</td>
<td>0.033</td>
</tr>
<tr>
<td>KABC SPI</td>
<td>-0.00 (0.02, 0.00)</td>
<td>0.036</td>
</tr>
<tr>
<td>BRIEF GEC</td>
<td>-0.00 (0.02, 0.00)</td>
<td>0.032</td>
</tr>
<tr>
<td>TOVA ADM</td>
<td>0.00 (0.02, 0.00)</td>
<td>0.047</td>
</tr>
<tr>
<td>TOVA DPrime</td>
<td>0.00 (0.02, 0.00)</td>
<td>0.040</td>
</tr>
</tbody>
</table>

SUMMARY
NVP or EFV at P1104s entry was associated with poorer neuropsychological scores than LPV/r (Figure 1), which persisted when controlling for nadir CD4 percent and time-varying HIV viral load (data not shown).

Other predictors of poorer scores in KABC domains included lower birth weight, WHO stage 4 disease and serious illness but not elevated VL on P1104 or due to loss of viral suppression from treatment failure.

CONCLUSIONS
Children receiving nevirapine or efavirenz while on P1104s had poorer neuropsychological scores as assessed by the KABC, BOT-2 and TOVA than those on lopinavir/ritonavir. Lopinavir/ritonavir is the preferred option for young children initiating ART. NVP may be related to poorer neuropsychological outcomes.

ACKNOWLEDGEMENTS
We gratefully acknowledge the contribution of all the participants and their families who participated in this study.

We acknowledge all the sites who participated in this study including the following:

South Africa: FAMCRU, Stellenbosch; Soeto IMPAACT, Johannesburg; Wits RH; Zimbabwe: MDC-JH, Kampala, Zimbabwe Family Care, Harare; Matadi: Malawi, Livingston.